That panel will meet to weigh whether the agency should allow Americans to have broader access to seven injectable peptides previously restricted over potential safety concerns.
As the Trump administration was assembling a key panel to review a slate of controversial peptides, FDA officials expressed concerns about appointing those who worked for peptide-related businesses a… [+187 chars]